Merck Prepares To Test Drive Biosimilar Pathway In The U.S.
This article was originally published in The Pink Sheet Daily
Executive Summary
Since the passage of healthcare reform legislation, many in the industry have questioned the viability of the biosimilar pathway, but Merck is ready to put it to the test.